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http://dx.doi.org/10.1016/j.kjms.201Abstract Several noninvasive indices have been proposed for predicting liver cirrhosis (LC),
particularly in chronic hepatitis C (CHC). In this study, noninvasive indices for predicting LC and
hepatocellular carcinoma (HCC) were compared. A total of 119 chronic hepatitis B (CHB)
patients and 240 CHC patients were evaluated in a hospital-based setting using various predic-
tors for pathologic LC such as aspartate aminotransferase/alanine aminotransferase (AST/ALT)
ratio (AAR), AAR-to-platelet ratio index (AARPRI), AST-to-platelet ratio index (APRI), age-
platelet (AP) index, and platelet counts. In addition, these indices were used to predict LC
[based on ultrasound (US)] in a community-based population of 201 patients with endemic
hepatitis C virus (HCV). These indices were evaluated for their ability to predict HCC in CHBepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital,
siung, Taiwan.
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386 P.-L. Tseng et al.and CHC patients (n Z 200). In CHB patients, the diagnostic performance of all indices was
inadequate for predicting LC (areas under receiver operating characteristic curves < 0.7).
Thrombocytopenia consistently demonstrated comparable accuracy to AARPRI  0.7 in CHB
and AP index  7.0 in CHC patients. The best cut-off values for APRI, AARPRI, and AP index
in predicting LC in CHC were 1.3, 0.8, and 7.0, respectively. The best cut-off values for APRI,
AARPRI, and AP index in predicting LC (based on US) were 1.0, 1.2, and 8.0, respectively, in
a HCV endemic community. An AAR > 1.4 might be a useful tool to identify candidates at high
risk for HCC. In conclusion, platelet count was both consistent and accurate in predicting LC.
An AAR > 1.4 is proposed as a possible surrogate marker for identifying patients at high risk for
developing HCC.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV)
infections cause liver fibrosis which often progresses to
liver cirrhosis (LC) [1,2]. Liver fibrosis is used as a param-
eter to guide antiviral treatment in chronic HBV and HCV
infection. Current guidelines recommended liver biopsy
before treatment in chronic hepatitis B patients with
persistently elevated or intermittently abnormal amino-
transferase levels and >105 copies/mL of HBV-DNA [3]. In
patients infected with HCV genotype 1, selected antiviral
therapy should include liver fibrosis to evaluate for possible
liver fibrosis [4].
Liver biopsy is the current gold standard for the detection
of liver fibrosis with some limitations including inter- and
intraobserver discrepancies and inadequate sample size
leading to underestimation in some cases [5,6]. This costly
procedure has significant complications in approximately
0.6e5% of patients [7,8]. Recently, elastography and other
sophisticated indices such as FibroTest have been reported
but are also expensive and not available in every hospital.
Hence, a simple and noninvasive method for predicting liver
fibrosis is needed. Among the reported noninvasive indices,
aspartate aminotransferase/alanine aminotransferase
(AST/ALT) ratio (AAR) [9], AST-to-platelet ratio index (APRI)
[10], platelet count [11, 12], Pohl score [13], and age-
platelet (AP) index [14] are based on routinely available
laboratory data. However, discrepant results have been re-
ported depending on the patient populations selected
[15,16]. Although these indices have been validated by
hospital-based studies of chronic HCV patients before anti-
viral therapy, such reports may be flawed by selection bias.
Few studies of noninvasive indices for chronic HBV patients
are currently available [12,17e19]. Moreover, the accuracy
of noninvasive indices is currently unknown in community
residents. A study comparing the accuracy of these indices in
chronic HBV and HCV patients and community residents can
help clarify the potential application and limitations of these
indices in predicting LC.
Most hepatocellular carcinoma (HCC) patients in Taiwan
and elsewhere have pre-existing HBV and/or HCV infection
[20,21]. According to previous reports, most HBV- and HCV-
related HCC cases are diagnosed in cirrhotic patients [22].
Therefore, surveillance is recommended for chronic HBV
and HCV patients [23], and limited HCC screening incirrhotic patients may be cost effective. In our previous
study, we proposed a two-stage HCC screening program,
that is, high-risk identification by a noninvasive serum
marker, such as thrombocytopenia, followed by ultrasound
(US) screening [24]. Noninvasive indices for predicting LC
and identifying candidates at high risk for HCC are needed
as part of HCC surveillance.
This study evaluated several noninvasive indices used for
predicting pathological LC in chronic HBV and HCV patients.
In addition, we studied the use of these indices in diag-
nosing LC (based on US) in HCV endemic residents. We also
compared the accuracy of these indices in predicting HCC
development in patients with different viral etiologies.
Patients and methods
The study was performed in accordance with the current
Declaration of Helsinki guidelines. The protocol was
approved by the Institutional Review Board of Chang Gung
Memorial Hospital, Taiwan. All patients gave their written
informed consent prior to participation in the study.
The present study was divided into three parts: Study 1
examined consecutive hospital-based patients to test for
any correlation between noninvasive indices and patho-
logical diagnosis of LC. Study 2 examined the validity of
these indices in LC using US in a small-scale community
study. Study 3 was a hospital-based study which determined
the proportion of HCC patients identified by these indices
based on their viral etiology.
Our previous study [24] revealed that the optimum cut-
off value for predicting LC using platelet counts was
150  109/L. At this cut-off value, sensitivity was 52.5% and
specificity was 78% in HBV patients. In HCV patients,
sensitivity was 68.2% and specificity was 76.4% using the
same cut-off value. A total of 48% of HCC patients were
thrombocytopenic.
In this report, data from the above studies were used to
test the validity and usefulness of other noninvasive indices
when compared to platelet counts. AST, ALT, and platelet
counts were routinely determined in the clinical laboratory.
The upper limit of normal (ULN) was 37 IU/L for AST and
40 IU/L for ALT. Laboratory parameters were available prior
to liver biopsy. From these routine laboratory values, AAR,
APRI, Pohl score, AP index, and platelet count were
calculated as described previously [9,10,13,14]. A new
Noninvasive indices for predicting LC 387index, AAR-to-platelet ratio index (AARPRI) derived from
FIB-4 by removing age, was also proposed as a predictor of
LC (Table 1).
Study 1. Correlation between noninvasive indices
and pathologically diagnosed LC
All chronic HBV and HCV patients from 1998 to 2001, with
available pathological diagnosis, were enrolled in this
study. This study included 122 chronic HBV patients and 244
chronic HCV patients. Those with chronic HBV were positive
for HBsAg (HBsAg V2, Abbott Laboratories Diagnostics Divi-
sion, IL, USA). Chronic HCV patients were positive for anti-
HCV (HCV version 3.0, Abbott Laboratories Diagnostics
Division, IL, USA). Patients with other concomitant causes
of liver disease such as autoimmune hepatitis or history of
alcohol abuse (exceeding 40 g/alcohol intake daily) were
excluded from the study. All patients underwent liver
needle biopsies (16-gauge, modified Menghini needle;
Hepafix; B. Braun Melsungen AG, Melsungen, Germany)
before beginning antiviral treatment at Kaohsiung Chang
Gung Memorial Hospital (KCGMH).
The mean length of the biopsy samples was1.8  0.8 cm
in chronic HBV patients and 1.7  0.7 cm in chronic HCV
patients. All histological grading [modified hepatic activity
index (HAI)] and staging (fibrosis score) were performed by
an experienced pathologist without knowledge of clinical
details or ultrasonographic findings [25]. Laboratory
parameters were available within 2 weeks prior to liver
biopsy. Three chronic HBV patients and four chronic HCV
patients with incomplete AST or ALT data were excluded
from statistical analysis.
Study 2. Validation of noninvasive indices for
predicting US LC in a HCV-endemic area
A total of 201 residents aged 40 years or older were
enrolled in this study. All individuals had participated in the
Adult Preventive Health Examination in 2001. All HBsAg,
anti-HCV, AST, ALT, a-fetoprotein (AFP), and complete
blood count tests as well as an upper abdominal US were
performed at the Min-Sheng Clinic, which is located in
Lieujia Township. The prevalence rates for HBsAg, anti-
HCV, both HBsAg and anti-HCV, and neither were 9.0%,Table 1 Routine laboratory parameters used to calculate nonin
Noninvasive indices Calculation
AAR AST/ALT
Pohl score Positive; AAR  1 and platelet  150 
AARPRI AAR/[platelet count ( 109/L)/150]
APRI [(AST/ULN)/platelet ( 109/L)]  100
AP index Age (y): <30 Z 0; 30e39 Z 1; 40e49 Z
50e59 Z 3; 60e69 Z 4; >70 Z 5
Platelet count ( 109/L): >225 Z 0; 20
175e199 Z 2; 150e174 Z 3; 125e149
AP index is the sum of the above (possi
AAR Z AST/ALT ratio; AARPRI Z AAR-to-platelet ratio index; AP in
ULN Z upper limit of normal, X Z including the factor.37.3%, 3.5% and 50.2%, respectively. The US machines used
were Toshiba SSA-220A or SSA-240A with 3.75-MHz convex
probes (Toshiba, Tokyo, Japan) [25]. Severity of liver
parenchymal disease was scored using a simplified scoring
system. Selected indicators were change of angle and edge
(0, neither; 1, either; 2, both), coarseness of liver paren-
chyma (0, normal; 1, mild; 2, definite), and splenomegaly
(0, none; 1, slight; 2, definite). The scoring system ranged
from 0 to 6, and scores of 5 or 6 were defined as cirrhosis
[26]. The US examinations were performed by five experi-
enced gastroenterologists. Prescreening training and post-
screening reviews were conducted to minimize
intraobserver variation and Kappa coefficient showed good
agreement between examiners. AAR, APRI, AARPRI, Pohl
score, AP index, and platelet count were used to predict
the diagnosis of LC based on US.
Study 3. Noninvasive markers coverage rate among
HCC patients
Study 3 compared the accuracy of noninvasive indices
including AAR, AARPRI, APRI, AP index, and platelet count in
predicting HCC. From 2006 to 2007, all KCGMH consecutive
patients with confirmed HCC by liver biopsy or with LC
without HCC as confirmed by liver biopsy were recruited for
analysis. AST, ALT, platelet counts, HBsAg, and anti-HCV
were determined before biopsy. Patients with unavailable
AST, ALT, or platelet count datawereexcluded fromanalysis.
Statistical analysis
Continuous variables were expressed as mean  standard
deviation (SD). Independent samples were compared by
Student t test or one-way analysis of variance. The contrast
factor was applied in a one-way analysis of variance to test
for linear trends. The sensitivity and specificity of contin-
uous variables for diagnosing LC were expressed by the
receiver operating characteristic (ROC) curve. The distance
between the sensitivity and specificity of each point and
the ideal point was calculated as distance Z [(1 e
sensitivity)2 þ (1 e specificity)2]1/2. The best cut-off point
was the point with the shortest distance or maximum
accuracy. The cut-off value was determined based on the
level of validity required. The difference between two ROCvasive indices of liver cirrhosis.
AST AAR Platelet Age
X X
109/L X X X
X X X
X X
2;
0e224 Z 1;
Z 4; <125 Z 5
ble value 0e10).
X O
dex Z age-platelet index; APRI Z AST-to-platelet ratio index;
388 P.-L. Tseng et al.curves was expressed as the difference between the areas
under the ROC curves (AUC) [27,28]. Diagnostic perfor-
mance was determined by the AUC of each index. Sensi-
tivity, specificity, positive predictive value (PPV), negative
predictive value (NPV), and accuracy were calculated for
each cut-off level.
The stratum-specific likelihood ratio (SSLR) is the prob-
ability of a test result within a given range or stratum when
disease is present, divided by the probability of the same
test result when disease is absent. We determined the SSLR
by means of the formula SSLRZ (x1/n1)/(x0/n0), where x1
is the number of patients in the stratum with HCC, n1 is the
total number with HCC, x0 is the number of patients in the
stratum without HCC, and n0 is the total number of patients
without HCC [29].
Results
Clinical characteristics of all populations
In total, 119 chronic HBV patients and 240 chronic HCV
patients who had undergone liver biopsy at KCGMH were
enrolled in Study 1. A total of 201 patients who had received
community adult health examination were enrolled in Study
2. Table 2 shows baseline clinical characteristics for all three
populations. Hospital-based patients were younger than
community residents (p < 0.001). AST and ALT levels were
higher in chronic HBV and chronic HCV patients compared
with the community group (p < 0.001). The prevalence of
cirrhosis was also higher in chronic HBV (32.5%) and chronic
HCV (27%) patients than in the community group (10.4%). In
the hospital group, the mean age was lower in chronic HBV
patients (39 12 years) compared with chronic HCV patients
(50  12 years) (p < 0.001).
Correlation between noninvasive tests and liver
fibrosis
No noninvasive indices correlated with fibrosis score in
chronic HBV patients (Fig. 1). AAR (p Z 0.028), APRI,Table 2 Clinical characteristics of hospitalized chronic hepatit
Variable CHB (n Z 119)
(Mean  SD)
Age (y) 39  12a
Male, n (%) 98 (81)
AST (IU/L) 86  106
ALT (IU/L) 194  502
Platelet count ( 109/L) 178  59
Stage F0e2, n (%) 69 (56.5)
F3e4, n (%) 53 (43.5)
Cirrhosis, n (%) 40 (32.5)e
CHB Z chronic hepatitis B; CHC Z chronic hepatitis C.
a CHC > CHB, p < 0.001.
b Compared with CHB or CHC, p < 0.001.
c Compared with CHC, p Z 0.017.
d Compared with CHB, p < 0.001; compared with CHC, p Z 0.003.
e Cirrhosis is confirmed as F4 by Knodell score.
f Diagnosed with images including ultrasonography.AARPRI, and AP index (p < 0.001) were increased with
fibrosis score, and platelet count (p < 0.001) was decreased
with fibrosis score in chronic HCV patients (Fig. 2).
Comparisons of ROC curve in predicting LC
Table 3 compares the reliability of AUC of AAR, APRI, AARPRI,
AP index, and platelet count in predicting LC. In chronic HBV
patients, AUCofAARPRI (0.693, CIZ 0.60e0.77) andplatelet
count (0.672, CIZ 0.58e0.76) were significantly higher than
APRI (0.529, CIZ 0.44e0.62). Although AARPRI had a higher
AUC value, it did not significantly differ from platelet count
or AAR in chronic HBV patients. The AUC of all indices for
chronic HBV patients was less than 0.7. In chronic HCV
patients, the AUC of APRI (0.742, CI Z 0.68e0.80), AARPRI
(0.744, CIZ 0.68e0.80), AP index (0.790, CIZ 0.73e0.84),
andplatelet count (0.801, CIZ 0.75e0.85)were significantly
higher than AAR (0.615, CIZ 0.55e0.68). In the community-
based study, the AUC of AAR (0.552, CI Z 0.48e0.62) was
significantly lower than in the other four tests in predicting
LCbasedonUS.TheAUCofAPRI, AP index, andplatelet count
all exceeded 0.90. Platelet count had higher AUC but did not
significantly differ from APRI and AP index in both hospital-
ized chronic HCV patients and HCV-endemic residents.
Sensitivity, specificity, PPV, and NPV cut-off levels
for different predictive indices in making the
pathological diagnosis of LC in chronic HBV and HCV
AAR, AARPRI, and AP index cut-off values for predicting LC in
chronic HBV patients were 0.6, 0.7, and 5.0, respectively
(Table 4). In chronic HBV patients, the sensitivity of these
indices was between 53% and 63% and specificity was
between 58% and 82%. AARPRI  0.7 and platelet
count  150  109/L had higher accuracy (73% and 70%,
respectively), and PPV (61% and 54%, respectively) for diag-
nosing LC compared with other indices in chronic HBV
patients. In chronic HCV patients, ARPI  1.3, AARPRI  0.8,
AP index  7.0, and platelet count  150  109/L were the
best cut-off levels for predicting LC (Table 5). The cut-offis B and C patients and HCV-endemic community residents.
CHC (n Z 240)
(Mean  SD)
Community (n Z 201)
(Mean  SD)
50  12a 59  12b
147 (60) 75 (37.3)
154  126 33  26b
97  72 34  36c
173  62 202  67d
143 (58.6)
101 (41.4)
66 (27)e 21 (10.4)f
Figure 1. Correlations between noninvasive indices and fibrosis score in chronic HBV patients (AeE). AAR (A), AARPRI (B), APRI
(C), AP index (D), and platelet count (E) (p > 0.05). No noninvasive indices correlated with fibrosis score in chronic HBV patients.
Figure 2. Correlations between noninvasive indices and fibrosis score in chronic HCV patients (AeE). AAR (A) (pZ 0.028), AARPRI
(B), APRI (C), and AP index (D) (p < 0.001) were increased with fibrosis score. Platelet count (E) (p < 0.001) was decreased with
fibrosis score.
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Table 3 Comparisons of AUC using different noninvasive methods for predicting liver cirrhosis.
Noninvasive indices Area under the receiver operating characteristic curve (AUC)
Chronic hepatitis B Chronic hepatitis C Community all
AAR 0.660 (0.57e0.74) 0.615 (0.55e0.68)b 0.552 (0.48e0.62)b
AARPRI 0.693 (0.60e0.77) 0.744 (0.68e0.80) 0.854 (0.80e0.90)
APRI 0.529 (0.44e0.62)a 0.742 (0.68e0.80) 0.908 (0.86e0.94)
Platelet count 0.672 (0.58e0.76) 0.801 (0.75e0.85) 0.931 (0.89e0.96)
AP Index 0.609 (0.52e0.70) 0.790 (0.73e0.84) 0.915 (0.87e0.95)
AAR Z AST/ALT; AARPRI Z AAR-to-platelet ratio index; AP index Z age-platelet index; APRI Z AST-to-platelet ratio index.
a Compared with AARPRI or platelet count, p < 0.05.
b Compared with APRI, AARPRI, AP index, or platelet count, p < 0.05.
390 P.-L. Tseng et al.values were higher in chronic HCV patients than in chronic
HBV patients. In chronic HCV patients, the sensitivity of
these indices was between 55% and 76% and specificity was
between 62% and 80%. AARPRI  0.8, AP index  7.0, and
platelet count 150 109/L had higher accuracy (73%, 75%,
and 74%, respectively), and PPV (51%, 53%, and 52%,
respectively) for diagnosing LC than the other indices in
chronic HCV patients. An AARPRI  0.8 had lower sensitivity
(55%) than the other two indices in chronic HCV patients. The
sensitivity at an APRI  1.3 (76%) was higher but specificity
(62%) was lower than the other indices. Hence, an AP
index  7.0 and platelet count  150  109/L were the
preferred tests. Moreover, platelet counts 150 109/L had
consistent diagnostic accuracy for LC in both chronicHBVand
HCV patients. Although the Pohl score had comparable
accuracy (75%), PPV (15%) was the lowest of all indices.Validation of noninvasive indices in HCV-endemic
communities
The best cut-off values for these indices for predicting
cirrhosis based on US in the HCV-endemic community were
ARPI  1.0, AARPRI  1.2, AP index  8.0, and plateletTable 4 Sensitivity, specificity, positive predictive value (PPV),
tests in detecting liver cirrhosis in chronic HBV patients.
CHB Sensitivity Specificity
AAR >0.6a 63% 58%
0.7 48% 73%
0.8 35% 84%
1.0 5% 92%
AARPRI 0.6 60% 72%
0.7a 55% 82%
0.8 45% 87%
1.0 23% 91%
AP index 5a 60% 66%
6 38% 82%
7 20% 87%
Platelet 150a 53% 78%
Pohl score (þ) 0% 96%
AARZ AST/ALT; AARPRIZ AAR-to-platelet ratio index; AP indexZ ag
hepatitis B.
a Selected cut-off value.
b Distance Z [(1 e sensitivity)2 þ (1 e specificity)2]1/2.count  150  109/L. Table 6 shows the sensitivity, speci-
ficity, PPV, NPV, and accuracy for predicting LC based on
US. A platelet count  150  109/L, an AP index  8.0 and
an APRI  1.0 had better diagnostic accuracy (86%, 87%,
and 91%, respectively) than either AAR or AARPRI for pre-
dicting LC based on US. Although APRI  1.0 had the best
accuracy (91%) and the best PPV (54%), it had lower sensi-
tivity (71%) compared with either AP index or platelet
count. The sensitivity of an AP index  8.0 (91%) was higher
than a platelet count  150  109/L (76%). However, it had
similar PPV and NPV to platelet count. Although the Pohl
score also had the comparable accuracy of 84%, this
measure exhibited inferior sensitivity (64%) in community
residents. Thus, we concluded that AP index and platelet
count were acceptable indices for predicting US LC based
on US in a HCV-endemic community.Basic characteristics of HCC patients and LC
patients without HCC
A total of 200 patients were enrolled in the study, including
127 newly diagnosed HCC patients and 73 LC patients
without HCC. The demographics and clinical characteristicsnegative predictive value (NPV), and accuracy of noninvasive
PPV NPV Accuracy Distanceb
43% 75% 60% 0.559
48% 73% 65% 0.586
52% 72% 67% 0.669
25% 66% 63% 0.953
52% 78% 68% 0.488
61% 78% 73% 0.484
64% 76% 73% 0.565
56% 70% 70% 0.775
46% 77% 64% 0.525
52% 73% 68% 0.645
42% 69% 65% 0.810
54% 77% 70% 0.518
0% 66% 64% 1.000
e-platelet index; APRIZ AST-to-platelet ratio index; CHB: chronic
Table 5 Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of noninvasive
tests in predicting liver cirrhosis in chronic HCV patients.
CHC Sensitivity Specificity PPV NPV Accuracy Distanceb
APRI 1.0 88% 49% 39% 92% 60% 0.523
1.2 83% 58% 43% 90% 65% 0.453
1.3a 76% 62% 43% 87% 66% 0.449
2.0 48% 78% 45% 80% 7%0 0.564
AARPRI 0.6 76% 57% 40% 82% 62% 0.492
0.7 61% 70% 44% 82% 68% 0.492
0.8a 55% 80% 51% 82% 73% 0.492
1.0 42% 87% 54% 80% 74% 0.594
AP index 6 83% 62% 45% 91% 68% 0.416
7a 70% 77% 53% 88% 75% 0.378
Platelet count 150a 68% 76% 52% 87% 74% 0.400
Pohl score (þ) 71% 75% 15% 98% 75% 0.382
AAR Z AST/ALT; AARPRI Z AAR-to-platelet ratio index; AP index Z age-platelet index; APRI Z AST-to-platelet ratio index;
CHC Z chronic hepatitis C.
a Selected cut-off value.
b Distance Z [(1 e sensitivity)2 þ (1 e specificity)2]1/2.
Noninvasive indices for predicting LC 391of all patients are summarized in Table 7. The patients with
HCC were significantly older than LC patients without HCC.
In LC patients, HCV infection was responsible for LC in the
LC patients with HCC; however, chronic HBV infection and
HCV infection were the major contributors to the devel-
opment of HCC in HCC patients.Comparisons of noninvasive indices in predicting
high-risk candidates of HCC
Thevaluesasassessedbyareasunder theROCcurves (AUROC)
in predicting HCC were 0.710 (95% CIZ 0.640e0.773), 0.597
(0.524e0.667), 0.580 (0.507e0.651), 0.572 (0.499e0.643),Table 6 Sensitivity, specificity, positive predictive value (PPV),
tests in detecting liver cirrhosis in a HCV-endemic community.
Community Sensitivity Specificity
APRI 1.0a 71% 93%
1.2 62% 95%
1.3 57% 95%
1.5 48% 96%
2.0 38% 98%
AARPRI 0.7 95% 39%
0.8 95% 49%
1.0 81% 68%
1.1 76% 73%
1.2a 76% 80%
AP index 6 95% 63%
7 95% 78%
8a 91% 87%
Platelet 150a 76% 88%
Pohl score (þ) 64% 87%
AAR Z AST/ALT; AARPRI Z AAR-to-platelet ratio index; AP index Z
a Selected cut-off value.
b Distance Z [(1 e sensitivity)2 þ (1 e specificity)2]1/2.and 0.558 (0.485e0.629) forAAR, AARPRI, APRI, AP index, and
platelet count, respectively (Fig. 3). The diagnostic accuracy
of AAR for HCC presence was superior to AARPRI (pZ 0.001),
APRI (pZ 0.013), AP index (pZ 0.008), and platelet count
(pZ 0.004).The optimal cut-off level in predicting high-risk
candidates of HCC
The cut-off value of AAR used in diagnosing the presence of
HCC,asdeterminedwith shortdistanceof [(1e sensitivity)2þ
(1 e specificity)2]1/2, was 1.2. The sensitivity and specificity
was 61.6% and 73.2% for all patients, 53.4% and 83.3% fornegative predictive value (NPV), and accuracy of noninvasive
PPV NPV Accuracy Distanceb
54% 96% 91% 0.298
59% 95% 92% 0.383
57% 95% 91% 0.433
56% 94% 91% 0.522
67% 93% 92% 0.620
15% 99% 45% 0.612
18% 99% 54% 0.512
23% 97% 70% 0.372
25% 96% 74% 0.361
31% 96% 80% 0.312
23% 99% 66% 0.373
34% 99% 80% 0.226
44% 99% 87% 0.158
42% 97% 86% 0.268
47% 93% 84% 0.382
age-platelet index; APRI Z AST-to-platelet ratio index.
Table 7 Demographics and clinical characteristics of patients with hepatocellular carcinoma (HCC) or liver cirrhosis patients
without HCC.
Patients with LC but without HCC (n Z 73) Patients with HCC (n Z 127) p
Age (y, mean  SD) 55.2  9.7 62.1  11.3 <0.001
Gender (%) 0.027
Male 47 (64.3) 100 (78.7)
Female 26 (35.7) 27 (21.3)
Etiology (%) 0.003
HBV 22 (30.1) 50 (39.4)
HCV 39 (53.4) 41 (32.3)
HBV þ HCV 8 (10.9) 10 (7.8)
Non-B/non-C 4 (5.5) 26 (20.5)
Liver cirrhosis (%) 73 (100)a 80 (64.1)b <0.001
BMI (kg/m2) 24.7  2.9 24.0  3.6 0.167
AST (IU/L) 88.2  49.3 86.2  64.8 0.824
ALT (IU/L) 106.1  74.3 74.1  71.5 0.03
Bilirubin (mg/dL) 1.11  0.50 1.53  4.03 0.387
AFP (ng/mL) 23.7  44.7 9924.4  4708.4 0.02
AFPZ a-fetoprotein; ALTZ alanine aminotransferase; ASTZ aspartate aminotransferase; BMIZ body mass index; HBVZ hepatitis B
virus; HCV Z hepatitis C virus; Non-B/non C Z etiology outside of HBV or HCV.
a Confirmed by pathology.
b Diagnosis with images including ultrasonography and/or computed tomography.
392 P.-L. Tseng et al.HBVpatients, 39.2% and 78.7% forHCVpatients, respectively.
The cut-off value, as determined with specificity more than
90%, was 1.4. The sensitivity and specificity was 36.8%
and 92.9% for all patients, 39.6% and 93.3% for HBV patients,
27.4% and 91.4% for HCV patients, respectively.
To estimate the likelihood ratios for the presence of
HCC, we ranked the values of AAR into three strata. For all
patients, the SSLR for HCC presence was 0.59 for AAR < 1.2,Figure 3. Receiver operating characteristic (ROC) curves for
AAR, AARPRI, APRI, AP index, and platelet count. The areas
under the ROC curves (AUROC) for HCC presence are 0.710,
0.597, 0.580, 0.572, and 0.558, respectively. AAR is superior to
AARPRI, APRI, AP index, and platelet count (p < 0.05).1.28 for AAR between 1.2 and 5.22 for AAR > 1.4, respec-
tively. Stratified according to virus etiology, SSLR was 0.56,
1.38, and 5.95 for AAR < 1.2, 1.2e1.4 and > 1.4 in HBV
patients, respectively. For HCV patients, SSLR was 0.77,
0.92, and 3.23 for AAR < 1.2, 1.2e1.4, and > 1.4, respec-
tively (Table 8). Irrespective of viral etiology, the relative
risk for the presence of HCC increased with the progression
of AAR values.
Discussion
Many direct and indirect serum markers are currently used
not only to predict liver fibrosis and LC but also to avoid
liver biopsies before antiviral therapy. Thrombocytopenia
as a surrogate of LC has also been used as a marker to
identify groups at high risk for developing HCC in HCV-
endemic areas. We compared noninvasive indices with
platelet count for predicting LC. The sensitivity of these
indices was also analyzed in predicting HCC patients.
Directed markers such as matrix protein collagens and
sophisticated indices such as FibroTest were not used for
comparison purposes in this study because they are expen-
sive and not routinely available. We used six simple indices
composed of four routine available factors: AST, ALT,
platelet count, and age. AAR and APRI used AST for pre-
dicting LC because an elevated AST in developing liver
fibrosis may be related to reduced AST clearance and mito-
chondria injury [30e32]. Thrombocytopenia, the simplest
serum surrogate for liver fibrosis is caused by decreased
thrombopoietin production [33,34], antibody mediated
platelet destruction [35], and myelotoxic effects [36]. Con-
founding factors are infectious and hematological diseases.
Age represents time lapse after HCV infection [37] and is
combined with platelet count to predict significant fibrosis
and necroinflammatory activity in HCV patients [14].
Table 8 The sensitivity, specificity, and likelihood ratio for the presence of hepatocellular carcinoma (HCC) stratified
according to all patients, patients with hepatitis B virus (HBV), or C virus infection (HCV) analyzed with stratum-specific like-
lihood ratio (SSLR) of AAR.
Cut-off values Sensitivity Specificity Strata Patients with LC
but without HCC
Patients
with HCC
SSLR
All patients (n Z 196)a
1.2 61.6% 73.2% <1.2 58 61 0.59
1.3 44.8% 87.3% 1.2e1.4 8 18 1.28
1.4 36.8% 92.9% >1.4 5 46 5.22
HBV patients (n Z 88)
1.2 53.4% 83.3% <1.2 25 27 0.56
1.3 46.5% 83.3% 1.2e1.4 3 8 1.38
1.4 39.6% 93.3% >1.4 2 23 5.95
HCV patients (n Z 98)
1.2 39.2% 78.7% <1.2 37 31 0.77
1.3 33.3% 85.1% 1.2e1.4 6 6 0.92
1.4 27.4% 91.4% >1.4 4 14 3.23
HBV Z hepatitis B virus; HCC Z hepatocellular carcinoma; HCV Z hepatitis C virus; SSLR Z stratum-specific likelihood ratio.
a Four patients with incomplete data were excluded from analysis.
Noninvasive indices for predicting LC 393All our indices were validated in three study pop-
ulations, that is, hospital chronic HBV patients, HCV
patients, and HCV-endemic community residents. The
choice of predictive index depended on the diagnostic
accuracy in different populations and the manner in which
they were utilized. In chronic HBV patients, all indices were
not accurate for predicting LC with AUC < 0.70. The
preferred tests, AARPRI  0.7 and platelet
count  150  109/L had better accuracy (73% and 70%,
respectively) in chronic HBV patients compared with other
tests. Platelet count proved superior to APRI for predicting
HBV-related LC similar to the finding of Wai et al. [12]. AST
is useful in predicting liver fibrosis in patients with chronic
HCV, but not in patients with chronic HBV and alcoholic
liver disease due to a differing pathogenesis. The new index
AARPRI, derived from FIB-4, used AST/ALT instead of AST to
adjust AST elevation caused by severe hepatic inflamma-
tion, which was different from APRI. The factors used in
this study are the same as those used for the Pohl score but
AARPRI is calculated as a continuous number. AAR had
a partial additional effect on platelet count in predicting LC
in chronic HBV patients. Because age is related to
progressive liver disease caused by HCV infections rather
than HBV infections, the AP index is inferior to platelet
count and AARPRI [37]. In hospitalized chronic HCV
patients, the AP index and platelet count are the preferred
tests.
Previous studies showed that thrombocytopenia had
a sensitivity between 77% and 91% and specificity exceeding
85% for predicting chronic HCV-related LC [9,31,37]. We
found that platelet count  150  109/L had lower sensi-
tivity (68%) and specificity (76%) in the current study than in
previous reports. The discrepancy may be explained by
variable platelet cut-off values and differing pathological
scoring systems. However, platelet count had a consistent
cut-off value and better diagnostic accuracy in chronic
hepatitis B and hepatitis C patients.
An AP index  6 revealed a sensitivity of 67% and spec-
ificity of 87% for predicting LC in a recent investigation [38].We found that an AP index  7 had similar sensitivity (70%)
but lower specificity (77%) than previous studies. We used
a higher AP index cut-off value due to the older mean age of
the population studied compared to previous studies. Age
did not affect the predictive accuracy for predicting LC in
chronic hepatitis C patients. The cut-off value of APRI was
1.3, which was lower than the value of 2.0 mentioned by
Wai et al. [10]. Compared to Wai et al., the sensitivity (48%)
and specificity (78%) of our APRI was less, even when we set
the cut-off value of 2.0.
In the HCV-endemic community, all indices used to
predict US diagnosed LC in the community based population
were not validated with liver biopsy as liver biopsy was not
feasible in all residents in this community. In our previous
study [26], US showed a sensitivity of 82.4% and specificity
of 70.7% for predicting LC in chronic HCV patients. Hence,
ultrasound was used for LC diagnosis instead of liver biopsy
in the community screen. The preferred tests for predicting
LC diagnosed by US were also the same as those used in
hospital HCV patients, except for APRI. APRI had a similar
AUC as the AP index and platelet count but was more
accurate. APRI had lower sensitivity (71%), higher speci-
ficity (93%), and better PPV (54%) compared with AP index
or platelet count. The cut-off value of APRI was lower in the
community than in the hospital group. Lower hepatic nec-
roinflammatory activity of community residents might
explain the differences. Age and AST would increase the
sensitivity and specificity of platelet count individually in
a HCV-endemic community study. The AAR and AAR-related
model, AARPRI, were satisfactory for predicting LC in
chronic HCV patients and HCV-endemic community resi-
dents. Our results were consistent with previous studies
[10,39,40].
The Pohl score was a categorical variable and was not
used for AUC comparisons. Although the Pohl score improved
PPV and NPV related to LC, decreased sensitivity may have
limited the numbers of patients who met the score.
Although this HCV-endemic community was not homoge-
neous enough to test the accuracy of noninvasive indices,
394 P.-L. Tseng et al.our purpose was to validate noninvasive indices in
a community setting, especially a HCV-endemic community.
SSLR was the statistical method used to evaluate the risk
of disease by a fixed optimal cut-off point. Because too
many strata cause the likelihood ratios to become unstable
and degenerate, we used only three strata. In addition, we
used an AAR of 1.4 as the cut-off value between medium
and higher strata as this point showed a significant differ-
ence between the two strata irrespective of viral etiology.
Surveillance of HCC requires determining a high enough
degree of risk of contracting HCC to trigger such surveil-
lance. Therefore, screening HCC in cirrhotic patients was
proposed. In clinical practice, both US and liver biopsy are
used to evaluate LC. However, these expensive methods
require substantial manpower and are not suitable for
large-scale community screening. The design of a two-stage
HCC screening program would rely upon budget, manpower,
and the evaluation of HCC patients using a noninvasive
index in a limited high-risk group. If a serum marker was
available for predicting LC in the first stage of community
screening, the high-risk HCC group would be readily iden-
tifiable. In the first stage, we suggested using the platelet
count to predict LC patients, and in the second stage, AAR
could be a suitable surrogate marker for HCC.
In conclusion, all noninvasive indices had poor diagnostic
accuracy for predicting LC in chronic HBV patients. A
platelet count of  150  109/L demonstrated consistently
acceptable predictive value for LC in all populations. In the
first stage of HCC screening, values of AARPRI  0.7 and
platelet count  150  109/L could be used for predicting
LC in HBV patients. In addition, values of AP index  7 and
platelet count  150  109/L could be used to predict LC in
HCV patients. In an HCV-endemic community, an
APRI  1.0, AP index  8, and platelet count  150  109/L
could be used for predicting high-risk LC groups. In the
second stage of HCC screening, an AAR > 1.4 could provide
sufficiency specificity to identify high-risk HCC patients.Acknowledgments
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